|
|
News Breaks | | | | February 20, 2013 | | 08:00 EDT |  | ZLCS | Zalicus granted composition-of-matter patent for Z944
Zalicus has been granted a patent by the U.S. Patent and Trademark office covering its product candidate Z944. United States patent number 8,377,968 entitled “N-Piperidinyl Acetamide Derivatives as Calcium Channel Blockers” provides broad coverage for Z944 including compositions of matter and certain therapeutic methods of use through April 2029. Z944 is a novel, oral, T-type calcium channel blocker which has demonstrated efficacy in a number of preclinical inflammatory pain models and other disease models. Z944 completed Phase 1 single and multiple ascending dose clinical studies in late 2012 and the Company plans to continue further clinical development with Z944 during 2013. | |
|
News For ZLCS From The Last 14 Days Check below for free stories on ZLCS the last two weeks. |
|
|
| June 4, 2013 | | 07:34 EDT | | ZLCS | Zalicus advancing clinical development of Z944 pain treatment
Zalicus announced that it is advancing Z944, its novel oral T-type calcium channel blocker, into further clinical development in the third quarter of 2013. The planned Phase 1b study is a state-of-the-art experimental clinical model utilizing Laser-Evoked Potentials to provide an efficient and objective assessment of the activity of Z944 in an induced neuropathic pain state. Results from the LEP study can further inform Zalicus’s development plans for Z944 in a variety of potential indications. | | | 07:28 EDT |  | ZLCS | Cambridge Healthtech Institute to host a conference
 Subscribe for More Information | |
|
|
|
|
|
|
